EUCTR2010-023772-71-IT进行中（未招募）不适用
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of MLN9708, a Next-Generation Proteasome Inhibitor, Administered in Combination with a Standard Care Regimen of Melphalan and Prednisone in Patients With Newly-Diagnosed Multiple Myeloma Requiring Systemic Treatment. - C16006
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 163
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female patient for whom standard MP treatment is indicated and who is not a candidate for HDT-SCT for 1 of the following reasons: The patient is 65 years of age or older. The patient is less than 65 years of age but has significant comorbid condition(s) that are likely to have a negative impact on tolerability of HDT-SCT. 2. Symptomatic MM or asymptomatic myeloma with myeloma-related organ damage diagnosed according to standard criteria 3. Patients must have measurable disease defined by at least 1 of the following 3 measurements: Serum M-protein = 1 g/dL (= 10 g/L) Urine M-protein = 200 mg/24 hours Serum free light chain assay: involved free light chain level = 10 mg/dL (= 100 mg/L), provided that the serum free light chain ratio is abnormal 4. Patients must meet the following clinical laboratory criteria within 3 days before the first dose of study treatment to be enrolled in the study: Absolute neutrophil count (ANC) = 1,000/mm3 and platelet count = 75,000/mm3. platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days prior to study drug dosing. Total bilirubin = 1.5 x the upper limit of the normal range (ULN). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 3 x ULN. Calculated creatinine clearance = 30 mL/min 5. ECOG performance status of 0 to 2 6. Female patients who: Are postmenopausal for at least 1 year before the screening visit, OR Are surgically sterile, OR If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 30 days after the last dose of study treatment, OR agree to completely abstain from heterosexual intercourse 7. Male patients, even if surgically sterilized (ie, status postvasectomy), who: Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study treatment, OR Agree to completely abstain from heterosexual intercourse Male patients must agree to not father a child and agree to use a latex condom during therapy and for 4 months after the last dose of study treatment, even if they have had a successful vasectomy, if their partner is of childbearing potential. 8. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 113
排除标准
- •1. Peripheral neuropathy = Grade 2 on clinical examination during the screening period. 2. Female patients who are lactating or pregnant. 3. Major surgery within 14 days before the first dose of study drug. (Note: kyphoplasty or vertebroplasty is not considered major surgery.) 4. Infection requiring systemic antibiotic therapy or other serious infection within 14 days before the first dose of study drug. 5. Diarrhea >Grade 1, based on the NCI CTCAE grading, in the absence of antidiarrheals. 6. Prior systemic therapy for MM, including investigational drugs. Prior treatment with corticosteroids or localized radiation therapy does not disqualify the patient (the maximum dose of corticosteroids should not exceed the equivalent of 160 mg of dexamethasone, a total of which can be given in a 2-week period. 7. Radiotherapy within 14 days before the first dose of study treatment. 8. Systemic treatment with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin), strong inhibitors of CYP3A (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort within 14 days before the first dose of study treatment. 9. Central nervous system involvement. 10. Diagnosis of smoldering MM, Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome, plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative syndrome. 11. Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months. 12. QTc > 470 msec on a 12-lead ECG obtained during the Screening period. If a machine reading is above this value, the ECG should be reviewed by a qualified reader and confirmed on a subsequent ECG. 13. Known or suspected human immunodeficiency virus (HIV) positive. 14. Known or suspected hepatitis B surface antigen-positive status orknown or suspected active hepatitis C infection. 15. Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol. 16. Known allergy to any of the study medications, their analogues, or excipients in the various formulations. 17. Known GI disease or GI procedure that could interfere with the oral absorption or tolerance of study drug, including difficulty swallowing. 18. Diagnosed or treated for another malignancy within 2 years before the first dose or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
研究者
相似试验
进行中（未招募）
1 期
A Phase 1/ 2 Study of the Oral Form of MLN9708 with Melphalan and Prednisone for Patients with Newly Diagnosed Multiple Myelomaewly diagnosed multiple myelomaMedDRA version: 16.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2010-023772-71-CZMillennium Pharmaceuticals, Inc158
进行中（未招募）
1 期
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of MLN9708, a Next-Generation Proteasome Inhibitor, Administered in Combination with a Standard Care Regimen of Melphalan and Prednisone in Patients With Newly-Diagnosed Multiple Myeloma Requiring Systemic Treatment.Estudio de fase 1/2, de aumento de dosis, abierto, de la formulación oral de MLN9708, un inhibidor de proteosoma de nueva generación, administrado en combinación con un régimen habitual de melfalán y prednisona en pacientes con mieloma múltiple de nuevo diagnóstico que precisan tratamiento sistémico -mieloma múltiple de nuevo diagnósticoMedDRA version: 12.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2010-023772-71-ESMillennium Pharmaceuticals, Inc163
进行中（未招募）
1 期
A Phase 1/ 2 Study of the Oral Form of MLN9708 with Melphalan and Prednisone for Patients with Newly Diagnosed Multiple MyelomaEUCTR2010-023772-71-GBMillennium Pharmaceuticals, Inc61
进行中（未招募）
1 期
Study to evaluate the effectiveness, safety and tolerability of nivolumaband the combination nivolumab plus other agents in subjects withadvanced liver cancer.MedDRA version: 21.0Level: LLTClassification code 10019829Term: Hepatocellular carcinoma recurrentSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10019830Term: Hepatocellular carcinoma resectableSystem Organ Class: 100000004864Hepatocellular carcinomaEUCTR2012-001514-42-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO620
招募中
1 期
A Phase 1/2, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Intravenous Doses of BMN 351 in Participants with Duchenne Muscular DystrophyMedDRA version: 20.0Level: PTClassification code: 10013801Term: Duchenne muscular dystrophy Class: 100000004850Duchenne Muscular DystrophyCTIS2023-506737-30-00Biomarin Pharmaceutical Inc.18